Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients

This publication has 12 references indexed in Scilit:

• Ritonavir boosted indinavir treatment as a simplified maintenance ‘mono'-therapy for HIV infection
  AIDS, 2004
• Incidence of Resistance in a Double‐Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir plus Stavudine and Lamivudine
  The Journal of Infectious Diseases, 2004
• Final analysis of the Trilège induction-maintenance trial: results at 18 months
  AIDS, 2002
• Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse‐Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1–Infected Protease Inhibitor–Experienced Patients
  The Journal of Infectious Diseases, 2002
• Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced Patients
  Journal of Virology, 2001
• ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results
  AIDS, 2001
• Drug Resistance and Predicted Virologic Responses to Human Immunodeficiency Virus Type 1 Protease Inhibitor Therapy
  The Journal of Infectious Diseases, 2000
• ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease
  Antimicrobial Agents and Chemotherapy, 1998
• Maintenance Antiretroviral Therapies in HIV-Infected Subjects with Undetectable Plasma HIV RNA after Triple-Drug Therapy
  New England Journal of Medicine, 1998
• Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy
  New England Journal of Medicine, 1997